The US is still far from becoming a single payer health care system. The recent push among progressive politicians for universal health care coverage under the Medicare for All banner has faded. But we are now faced with an unusual situation in which Medicare will be the primary payer, by far, for a class of drugs that could treat millions of people. And the program has decided it needs a uniform national approach to covering them.
The reimbursement policy could have an outsized influence on the uptake of the treatments as well as on the financials of the drug developers involved, and even future research and...
